Length 
170 pages

Date published 
April 2007

Additional info 
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

For Corporate Subscriptions, Multi-Reports Orders, Discounts or Order Questions.  

Contact:
Kerri Kelley
Customer Service
781-972-1347 



Metabolic and Inflammatory Disease R&D Tables and Figures

Metabolic and Inflammatory Disease R&D: An Assessment of 5 Highly Promising Therapeutic Classes

By Peter Norman, MBA, PhD 

FIGURES

Figure 4.1. SWOT Analysis for Chemokine Antagonists
Figure 4.2. Total Literature Activity in the Chemokine Receptor Field, 2000 to 2006
Figure 4.3. Literature Activity by Year in CCR Chemokine Receptor Field, 2000 to 2006
Figure 4.4. Patent Activity by Year in CCR Chemokine Receptor Field, 2000 to 2006
Figure 4.5. Literature Activity by Year in CXCR Chemokine Receptor Field, 2000 to 2006
Figure 4.6. Patent Activity by Year in CXCR Chemokine Receptor Field, 2000 to 2006
Figure 4.7. Patent Activity by Company, for Both CCR and CXCR Antagonists, 2000 to 2006
Figure 5.1. SWOT Analysis for TLR-4 Antagonists
Figure 5.2. SWOT Analysis for TLR-7 Agonists
Figure 5.3. SWOT Analysis for TLR-9 Agonists
Figure 5.4. Increasing Literature Interest in TLRs, 2000 to 2006
Figure 5.5. Patent Activity in TLRs, 2000 to 2006
Figure 5.6. Interest in Patenting TLR Agonists and Antagonists, 2000 to 2006
Figure 6.1. SWOT Analysis for 11β-HSD1
Figure 6.2. Literature and Patent Activity in the 11β-HSD Field, 2000 to 2006
Figure 6.3. Patents Claiming 11β-HSD from Major Companies and Selected Other Companies
Figure 7.1. SWOT Analysis for MC4 Receptor Agonists
Figure 7.2. Increasing Interest in MC Receptors and Their Modulators, 1999 to 2006
Figure 7.3. Patent Activity by Company in Melanocortin Agonists
Figure 8.1. SWOT Analysis for MCH-1 Antagonists
Figure 8.2. Increasing Interest in MCH-1 Receptor and MCH-1 Antagonists, 2000 to 2006
Figure 8.3. Patent Activity from Leading Players in the MCH-1 Antagonist Field

TABLES

Table 1.1. Numbers of Potential Drug Targets of Selected Classes Within the Human Genome
Table 2.1. Development Time Frame of Leading Dipeptidyl Peptidase IV Inhibitors
Table 3.1. Novel Anti-inflammatory Approaches to the Treatment of Arthritis
Table 3.2. Novel Approaches to the Treatment of Diabetes
Table 3.3. Novel Approaches to the Treatment of Obesity
Table 3.4. Novel Approaches to the Treatment of Lipid Disorders
Table 4.1. Chemokine CCR Receptors, Preferred Chemokine Ligand(s), and Main Cellular Expression
Table 4.2. Chemokine CXCR Receptors, Preferred Chemokine Ligand(s), and Main Cellular Expression
Table 4.3. Chemokine Antagonists that Were in Clinical Development for Indications Other than HIV Infection
Table 4.4. Chemokine Antagonists that Are Currently in Clinical Development for Indications Other than HIV Infection
Table 4.5. Chemokine Antagonists Disclosed as Being in Preclinical Development or Discovery for Indications Other than HIV Infection
Table 5.1. Summary of the Human TLRs: Their Natural Ligands and Their Expression Patterns
Table 5.2. Identified TLR Modulators and Their Development Status as of December 2006
Table 6.1. 11β-HSD1 Inhibitors in Clinical or Preclinical Development as of December 2006
Table 7.1. Identified MC Receptor Modulators and Their Development Status as of December 2006
Table 8.1. Identified MCH-1 Antagonists and Their Development Status as of December 2006